RESUMO
INTRODUCTION: We have developed the first international evidence-based guideline for the diagnosis and management of polycystic ovary syndrome (PCOS), with an integrated translation program incorporating resources for health professionals and consumers. The development process involved an extensive Australian-led international and multidisciplinary collaboration of health professionals and consumers over 2 years. The guideline is approved by the National Health and Medical Research Council and aims to support both health professionals and women with PCOS in improving care, health outcomes and quality of life. A robust evaluation process will enable practice benchmarking and feedback to further inform evidence-based practice. We propose that this methodology could be used in developing and implementing guidelines for other women's health conditions and beyond. Main recommendations: The recommendations cover the following broad areas: diagnosis, screening and risk assessment depending on life stage; emotional wellbeing; healthy lifestyle; pharmacological treatment for non-fertility indications; and assessment and treatment of infertility. Changes in management as a result of this guideline: â¢Diagnosis:âªwhen the combination of hyperandrogenism and ovulatory dysfunction is present, ultrasound examination of the ovaries is not necessary for diagnosis of PCOS in adult women;âªrequires the combination of hyperandrogenism and ovulatory dysfunction in young women within 8 years of menarche, with ultrasound examination of the ovaries not recommended, owing to the overlap with normal ovarian physiology; andâªadolescents with some clinical features of PCOS, but without a clear diagnosis, should be regarded as "at risk" and receive follow-up assessment.â¢Screening for metabolic complications has been refined and incorporates both PCOS status and additional metabolic risk factors.â¢Treatment of infertility: letrozole is now first line treatment for infertility as it improves live birth rates while reducing multiple pregnancies compared with clomiphene citrate.
Assuntos
Gerenciamento Clínico , Medicina Baseada em Evidências/normas , Internacionalidade , Síndrome do Ovário Policístico/terapia , Medicina Reprodutiva/normas , Adolescente , Adulto , Clomifeno/uso terapêutico , Medicina Baseada em Evidências/métodos , Feminino , Humanos , Infertilidade Feminina/tratamento farmacológico , Letrozol/uso terapêutico , Síndrome do Ovário Policístico/diagnóstico , Gravidez , Medicina Reprodutiva/métodos , Adulto JovemRESUMO
In this paper, we describe the robust governance structures and processes underpinning the development of the first International Evidence-Based Guideline for the Assessment and Management Polycystic Ovary Syndrome (2018). The guideline was an outcome of the Centre of Research Excellence for Polycystic Ovary Syndrome, and an example of a transformative, strategic research initiative to impact delivery model. The governance structure supported and delivered critical ethical and regulatory outcomes, including: broad and diverse representation across health professional and consumer groups and exceeded regulatory standards; adherence to rigorous knowledge creation processes; and compliance with the standards for guidelines set by the approval body, the Australian National Health and Medical Research Council (NHMRC). Well-articulated and appropriately implemented governance structures that meet the complex nature of contemporary research and translation activities are essential to enable distributed leadership and to deliver key outcomes.